加纳临床诊断1型糖尿病患者的C肽分泌异质性
该病例对照研究纳入加纳266例临床诊断并胰岛素治疗的长期1型糖尿病患者和266例健康对照,按随机C肽水平分组比较临床特征、HLA单倍型、自身抗体及炎症代谢谱。仅28.9%患者C肽低,其余为中或高水平,且自身抗体和HLA风险关联较低,提示需更好区分非典型糖尿病。
要点
- 临床诊断1型糖尿病中仅28.9%C肽低(<0.2 nmol/l)。
- 34.6%和36.5%患者C肽处于中(0.2-0.6 nmol/l)或高水平(>0.6 nmol/l)。
- 中/高C肽亚组自身抗体滴度低且携带保护性HLA单倍型。
核心结论
- 加纳长期临床诊断1型糖尿病患者中约三分之二维持C肽分泌,且缺乏自身抗体和HLA风险关联,需与不典型糖尿病鉴别以优化诊疗。
研究设计与样本
- 加纳病例对照研究,纳入266例临床诊断并胰岛素治疗的长期1型糖尿病患者和266例健康对照。
主要发现
- 仅28.9%患者C肽低(<0.2 nmol/l),为最年轻最瘦组,HLA II类风险单倍型及GAD、ZnT8自身抗体频率高于其他组。
- 34.6%和36.5%患者分别为中(0.2-0.6 nmol/l)和高(>0.6 nmol/l)C肽水平,其自身抗体滴度低且携带一种保护性HLA II类单倍型。
- 高C肽组起病时酮症最普遍;芳香族和支链氨基酸在糖尿病亚组间有差异并与C肽水平正相关。
临床怎么用
- 对临床诊断1型糖尿病但病程长且仍维持C肽者,应考虑检测C肽、自身抗体和HLA以重新分类。
- 在资源有限地区,识别非典型糖尿病有助优化个体化治疗和医疗资源配置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In sub-Saharan Africa, type 1 diabetes is typically diagnosed clinically, which can be challenging due to atypical diabetes presentations such as ketosis-prone type 2 diabetes or type 2 diabetes in the absence of overweight and obesity. C-peptide, a marker of residual insulin secretion capacity, is crucial for understanding these variations but understudied in the region. Here, we investigated whether C-peptide measurement and concomitant genetic, autoimmune and metabolic characterisation of individuals with clinically diagnosed type 1 diabetes confirm diabetes classification and highlight population-specific features. METHODS: In this case-control study from Ghana, we recruited 266 individuals with clinically diagnosed and insulin-treated long-term type 1 diabetes and 266 healthy control individuals. We compared clinical features, HLA class II haplotypes, autoantibodies, and inflammatory and metabolic serum profiles across control and patient groups classified by random C-peptide levels: low (<0.2 nmol/l), mid (0.2-0.6 nmol/l) and high (>0.6 nmol/l). RESULTS: Only 28.9% of individuals with clinically diagnosed type 1 diabetes had low C-peptide concentrations. They were the youngest and leanest group, with higher frequencies of HLA class II risk haplotypes and GAD and ZnT8 autoantibodies compared with all other groups. By contrast, 34.6% and 36.5% had mid-range or high C-peptide levels, respectively. These subgroups resembled the control group in terms of low autoantibody titres and one protective HLA class II haplotype. Ketosis at onset was most prevalent in individuals with high C-peptide. Serum proinflammatory biomarkers differed between individuals with diabetes and control participants, but not between C-peptide subgroups. Aromatic and branched-chain amino acids varied between diabetes subgroups and positively correlated with C-peptide levels. CONCLUSIONS/INTERPRETATION: Maintained C-peptide levels in two-thirds of individuals with long-term type 1 diabetes in Ghana, combined with the absence of autoantibodies and HLA risk association, highlight the necessity for better differentiation from atypical diabetes presentations to optimise patient care and improve health outcomes in resource-limited settings.
引用
- Aniagyei W, Sarfo-Kantanka O, Mohayideen S, et al. Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana. Diabetologia. 2025. PMID: 41175199. doi:10.1007/s00125-025-06576-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。